OptiDose Technology
Catalent's OSDrC OptiDose enables the design of dividable, multi-layer, single or multi-core tablets with a practically endless variety of core numbers, shapes, sizes, and placement within the tablet.
OptiDose Technology
Catalent’s OSDrC® OptiDose™ enables design of dividable, multi-layer, single or multi-core tablets with a practically endless variety of core numbers, shapes, sizes, and placement. The flexible-core capability provides new alternatives in controlled release designs for drug formulators, developers, and marketers in a high quality, one step manufacturing processes. This expands tableting capabilities in many areas that differentiate beyond existing technologies.
OptiDose technology provides the flexibility to design single or multiple API in a single tablet, with different release profiles. In addition to shown improvement in mass variability between layers, OptiDose also offers tablet design to minimize cross-layer interaction of API and improved product stability.
One of the more recognized approaches for developing high quality controlled release formulations, Wurster fluid bed technology is a bottom-spray approach, where a coating medium is sprayed onto the particle. Compared to alternative technologies, it produces a more consistent coating for powders, granules, pellets, and micro-tablets, with higher quality controlled release product due to more predictable residence time within the coating zone.
Catalent recently invested in major capacity expansions at its Schorndorf, Germany; Somerset, NJ; and Winchester, KY, facilities to increase fluid bed capacity and capabilities to meet growing customer demand.
Company name: Catalent Pharma Solutions
Website: www.catalent.com
E-mail: info@catalent.com
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
